Table 1.
Baseline characteristics of the training and validation cohorts.
| Variables | Training set (N = 401) | Validation set (N = 276) | ||||
|---|---|---|---|---|---|---|
| PB group (N = 78) | NB group (N = 323) | P-value | PB group (N = 56) | NB group (N = 220) | P-value | |
| Age (years) | 68.410 ± 8.067 | 67.879 ± 8.479 | 0.606 | 70.946 ± 8.192 | 68.986 ± 8.714 | 0.130 |
| PV (cm3) | 38.431 (25.544–51.170) | 59.486 (43.186–79.765) | < 0.001 | 39.262 (27.073–56.406) | 59.574 (41.710–83.025) | < 0.001 |
| fPSA/tPSA | 0.132 (0.080–0.176) | 0.187 (0.141–0.247) | < 0.001 | 0.140 (0.094–0.177) | 0.184 (0.142–0.228) | < 0.001 |
| PSAD | 0.180 (0.123–0.277) | 0.101 (0.079–0.148) | < 0.001 | 0.174 (0.108–0.279) | 0.107 (0.076–0.148) | < 0.001 |
| NLR | 2.471 (2.012–3.239) | 2.275 (1.703–3.147) | 0.079 | 2.404 (2.021–3.298) | 2.234 (1.675–3.209) | 0.347 |
| LMR | 3.610 (2.710–4.543) | 4.278 (3.349–5.465) | < 0.001 | 3.583 (2.736–5.194) | 4.182 (3.047–5.923) | 0.025 |
| PLR | 124.9 (92.8–155.7) | 113.4 (90.2–147.8) | 0.175 | 119.6 (92.4–152.3) | 107.8 (85.7–154.5) | 0.112 |
| RDW-SD (fl) | 43.2 (41.5–45.8) | 44.3 (42.4–46.4) | 0.011 | 43.1 (41.2–45.8) | 44.5 (42.6–46.9) | 0.005 |
PB positive-biopsy, NB negative-biopsy, fPSA free/total prostate specific antigen, tPSA total prostate specific antigen, PV prostate volume, PSAD prostate specific antigen density, NLR neutrophil-to-lymphocyte ratio, LMR lymphocyte to monocyte ratio, PLR platelet to lymphocyte ratio, RDW-SD standard deviation of red blood cell distribution width.